Analyst Rating Update on Sequenom (SQNM)

Sequenom (NASDAQ:SQNM) : The consensus on Sequenom (NASDAQ:SQNM) based on 4 analyst recommendation on the company stock is 3, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Sequenom (NASDAQ:SQNM) stock is expected to deviate a maximum of $0.5 from the average target price of $1.43 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $2 and the most muted being $1.

Company shares have received an average consensus rating of Hold for the current week

Sequenom (NASDAQ:SQNM): stock turned positive on Tuesday. Though the stock opened at $0.95, the bulls momentum made the stock top out at $1.02 level for the day. The stock recorded a low of $0.95 and closed the trading day at $0.9805, in the green by 3.21%. The total traded volume for the day was 689,390. The stock had closed at $0.95 in the previous days trading.

In an insider trading activity, Beaver Carolyn, CFO of Sequenom Inc had purchased 30,000 shares on June 10, 2016 in a transaction. The price per share was $1.1 and the total amount of the disclosed transaction was $33,000.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.